EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino

EyePoint, Inc.

Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.
Ribeiro joins from Apellis, where he led global Phase 3 GA program and FDA approval of SYFOVRE.
Company on track to report Phase 2 PAVIA topline data for EYP-1901 in NPDR in Q2 2024.
Initiation of Phase 3 LUGANO trial for EYP-1901 in wet AMD expected in second half 2024.
Board granted 125,000 stock options as inducement award to Ribeiro under Nasdaq Rule 5635(c)(4).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.